Bleeding and thrombosis in myeloproliferative disorders

Area of Science:

• Hematology
• Oncology
• Vascular Medicine

Background:

• Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by hemostatic imbalance.
• Patients often present with hemorrhagic tendencies, particularly those with high platelet counts, exhibiting features of acquired von Willebrand's disease.
• The primary therapeutic challenge lies in managing the increased risk of arterial and venous thromboses.

Purpose of the Study:

• To reassess the clinical epidemiology of hemostatic manifestations in PV and ET.
• To explore the rationale and efficacy of low-dose aspirin for managing microcirculatory disturbances and thrombosis risk.
• To highlight the need for further research into chemotherapeutic risks and alternative cytoreductive strategies.

Main Methods:

• Analysis of data from large retrospective studies on clinical epidemiology.
• Observation of aspirin's selective sensitivity in treating erythromelalgia and microcirculatory disturbances.
• Consideration of thromboxane A2 hyperproduction in PV and ET subjects.

Main Results:

• Erythromelalgia and other microcirculatory disturbances are notably sensitive to aspirin.
• Thromboxane A2 hyperproduction is a documented feature in PV and ET patients.
• A large-scale randomized trial is underway to evaluate aspirin's efficacy and safety in PV.

Conclusions:

• Low-dose aspirin provides a rationale for managing specific microcirculatory disturbances in PV and ET.
• Further clinical studies are essential to define the neoplastic risks of chemotherapy and the effectiveness of alternative treatments.
• Understanding and managing hemostatic imbalance remains critical for patients with PV and ET.